Please use this identifier to cite or link to this item:
Title: Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma
Authors: Goggi, Julian L.
Ramasamy, Boominathan
Tan, Yun Xuan
Hartimath, Siddesh V.
Tang, Jun Rong
Cheng, Peter
Msallam, Rasha 
Chacko, Ann-Marie 
Hwang, You Yi
Robins, Edward G. 
Issue Date: 9-Dec-2021
Publisher: Hindawi Limited
Citation: Goggi, Julian L., Ramasamy, Boominathan, Tan, Yun Xuan, Hartimath, Siddesh V., Tang, Jun Rong, Cheng, Peter, Msallam, Rasha, Chacko, Ann-Marie, Hwang, You Yi, Robins, Edward G. (2021-12-09). Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma. Molecular Imaging 2021 : 9305277. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Hepatocellular carcinoma (HCC) is a notoriously difficult cancer to treat. The recent development of immune checkpoint inhibitors has revolutionised HCC therapy; however, successful response is only observed in a small percentage of patients. Biomarkers typically used to predict treatment response in other tumour types are ineffective in HCC, which arises in an immune-suppressive environment. However, imaging markers that measure changes in tumour infiltrating immune cells may supply information that can be used to determine which patients are responding to therapy posttreatment. We have evaluated [18F]AlF-mNOTA-GZP, a radiolabeled peptide targeting granzyme B, to stratify response to ICIs in a HEPA 1-tumours, a syngeneic model of HCC. Posttherapy, in vivo tumour retention of [18F]AlF-mNOTA-GZP was correlated to changes in tumour volume and tumour-infiltrating immune cells. [18F]AlF-mNOTA-GZP successfully stratified response to immune checkpoint inhibition in the syngeneic HEPA 1-6 model. FACS indicated significant changes in the immune environment including a decrease in immune suppressive CD4+ T regulatory cells and increases in tumour-associated GZB+ NK+ cells, which correlated well with tumour radiopharmaceutical uptake. While the immune response to ICI therapies differs in HCC compared to many other cancers, [18F]AlF-mNOTA-GZP retention is able to stratify response to ICI therapy associated with tumour infiltrating GZB+ NK+ cells in this complex tumour microenvironment. © 2021 Julian L. Goggi et al.
Source Title: Molecular Imaging
ISSN: 1536-0121
DOI: 10.1155/2021/9305277
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2021_9305277.pdf890.42 kBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons